Glaxo, Merck Ebola Vaccine Trials to Start in West Africa
This article is for subscribers only.
Late-stage trials of Ebola vaccines may begin in Liberia by the end of this month, and in Sierra Leone and Guinea in February, the World Health Organization said.
The trial in Liberia will test an experimental vaccine from GlaxoSmithKline Plc and another developed jointly by Merck & Co. and NewLink Genetics Corp. in about 27,000 people, Marie-Paule Kieny, the WHO’s assistant director-general of health systems and innovation, said at a Geneva briefing today.